Prelude Therapeutics (PRLD) Amortizatization of Intangibles (2021 - 2026)
Prelude Therapeutics (PRLD) reported Amortizatization of Intangibles of $388000.0 for Q1 2026, up 591.14% on a YoY basis from $56139.2 in Q1 2025, and up 106.38% sequentially from $188000.0 in Q4 2025.
Prelude Therapeutics (PRLD) Amortizatization of Intangibles (2021 - 2026) Analysis & Trends
Prelude Therapeutics (PRLD) has 6 years of Amortizatization of Intangibles data on file, last reported at $388000.0 in Q1 2026.
- For the quarter ending Q1 2026, Amortizatization of Intangibles rose 591.14% year-over-year to $388000.0; the trailing twelve-month figure through Mar 2026 stood at $838000.0 (down 72.24% YoY), and the FY2025 full-year result was $371000.0, down 92.0% from the prior year.
- Amortizatization of Intangibles advanced to $388000.0 in Q1 2026, from $188000.0 in the prior quarter.
- In the past five years, Amortizatization of Intangibles ranged from a high of $1.6 million in Q3 2023 to a low of -$1.0 million in Q2 2022.
- A 5-year average of $369411.8 and a median of $359000.0 in 2023 frame the typical range for Amortizatization of Intangibles.
- Across the five-year window, Amortizatization of Intangibles tumbled 105.13% in 2025 and soared 591.14% in 2026, its largest moves.
- Tracing PRLD's Amortizatization of Intangibles over 5 years: stood at $179000.0 in 2022, then soared by 498.32% to $1.1 million in 2023, then dropped by 11.2% to $951000.0 in 2024, then plunged by 80.23% to $188000.0 in 2025, then jumped by 106.38% to $388000.0 in 2026.
- Business Quant data shows PRLD's Amortizatization of Intangibles at $388000.0 in Q1 2026, $188000.0 in Q4 2025, and $49000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 3.22 Mn |
| 10 | Prelude Therapeutics | 322.24 Mn | 177.64 Mn | - | 388,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 388,000.00 |
| Mar 31, 2026 | 388,000.00 |
| Dec 31, 2025 | 188,000.00 |
| Dec 31, 2025 | 188,000.00 |
| Sep 30, 2025 | 49,000.00 |
| Sep 30, 2025 | 49,000.00 |
| Jun 30, 2025 | 213,000.00 |
| Jun 30, 2025 | 213,000.00 |
| Mar 31, 2025 | -79,000.00 |
| Mar 31, 2025 | -79,000.00 |
| Dec 31, 2024 | 951,000.00 |
| Dec 31, 2024 | 951,000.00 |
| Sep 30, 2024 | 815,000.00 |
| Sep 30, 2024 | 815,000.00 |
| Jun 30, 2024 | 1.33 Mn |
| Jun 30, 2024 | 1.33 Mn |
| Mar 31, 2024 | 1.54 Mn |
| Mar 31, 2024 | 1.54 Mn |
| Dec 31, 2023 | 1.07 Mn |
| Dec 31, 2023 | 1.07 Mn |